1. Academic Validation
  2. Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906

Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906

  • Sci Rep. 2017 Jun 23;7(1):4119. doi: 10.1038/s41598-017-04304-5.
Kazuki Tajima 1 Jun Shirakawa 2 Yu Togashi 1 Shunsuke Yamazaki 1 Tomoko Okuyama 1 Mayu Kyohara 1 Hiromi Konishi 1 Yasuo Terauchi 3
Affiliations

Affiliations

  • 1 Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama-City University, Yokohama, Japan, 236-0004, Japan.
  • 2 Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama-City University, Yokohama, Japan, 236-0004, Japan. jshira-tky@umin.ac.jp.
  • 3 Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama-City University, Yokohama, Japan, 236-0004, Japan. terauchi-tky@umin.ac.jp.
Abstract

Growth factor signaling via Insulin Receptor (IR) and IGF-1 receptor (IGF1R) plays several important roles in the pathogenesis of metabolic syndrome and diabetes. OSI-906 (linsitinib), an anti-tumor drug, is an orally bioavailable dual inhibitor of IR and IGF1R. To investigate the recovery from metabolic changes induced by the acute inhibition of IR and IGF1R in adult mice, mice were treated with OSI-906 or a vehicle for 7 days and the results were analyzed on the last day of injection (Day 7) or after 7 or 21 days of withdrawal (Day 14 or Day 28). On day 7, the visceral white fat mass was significantly reduced in mice treated with OSI-906 accompanied by a reduced expression of Leptin and an increased expression of the lipolysis-related genes Lpl and ATGL. Interestingly, the lipoatrophy and the observed changes in gene expression were completely reversed on day 14. Similarly, liver steatosis and β cell proliferation were transiently observed on day 7 but had disappeared by day 14. Taken together, these results suggest that this model for the acute inhibition of systemic IR/IGF1R signaling may be useful for investigating the recovery from metabolic disorders induced by impaired growth factor signaling.

Figures
Products